網膜静脈閉塞症治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Retinal Vein Occlusion - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0581
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:107
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Retinal Vein Occlusion – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion – Pipeline Review, H2 2019, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 6, 2, 4 and 1 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinal Vein Occlusion – Overview
Retinal Vein Occlusion – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Retinal Vein Occlusion – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinal Vein Occlusion – Companies Involved in Therapeutics Development
3SBio Inc
Addmedica SAS
Aerpio Pharmaceuticals Inc
Annexin Pharmaceuticals AB
Calpain Therapeutics Pty Ltd
Cell Medica Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Eyevensys SAS
Gene Signal International SA
Graybug Vision Inc
Kodiak Sciences Inc
Lupin Ltd
NeuBase Therapeutics Inc
Novartis AG
Ocular Therapeutix Inc
Outlook Therapeutics Inc
Oxurion NV
Panoptes Pharma GesmbH
Retinal Vein Occlusion – Drug Profiles
Retinal Vein Occlusion – Dormant Projects
Retinal Vein Occlusion – Discontinued Products
Retinal Vein Occlusion – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Retinal Vein Occlusion, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Retinal Vein Occlusion - Pipeline by 3SBio Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Addmedica SAS, H2 2019
Retinal Vein Occlusion - Pipeline by Aerpio Pharmaceuticals Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Annexin Pharmaceuticals AB, H2 2019
Retinal Vein Occlusion - Pipeline by Calpain Therapeutics Pty Ltd, H2 2019
Retinal Vein Occlusion - Pipeline by Cell Medica Ltd, H2 2019
Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2019
Retinal Vein Occlusion - Pipeline by Eyevensys SAS, H2 2019
Retinal Vein Occlusion - Pipeline by Gene Signal International SA, H2 2019
Retinal Vein Occlusion - Pipeline by Graybug Vision Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Kodiak Sciences Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Lupin Ltd, H2 2019
Retinal Vein Occlusion - Pipeline by NeuBase Therapeutics Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Novartis AG, H2 2019
Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Outlook Therapeutics Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Oxurion NV, H2 2019
Retinal Vein Occlusion - Pipeline by Panoptes Pharma GesmbH, H2 2019
Retinal Vein Occlusion - Dormant Projects, H2 2019
Retinal Vein Occlusion - Discontinued Products, H2 2019

【掲載企業】

3SBio Inc
Addmedica SAS
Aerpio Pharmaceuticals Inc
Annexin Pharmaceuticals AB
Calpain Therapeutics Pty Ltd
Cell Medica Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Eyevensys SAS
Gene Signal International SA
Graybug Vision Inc
Kodiak Sciences Inc
Lupin Ltd
NeuBase Therapeutics Inc
Novartis AG
Ocular Therapeutix Inc
Outlook Therapeutics Inc
Oxurion NV
Panoptes Pharma GesmbH

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[網膜静脈閉塞症治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆